[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"behcet-disease-and-vascular-involvement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:behcet-disease-and-vascular-involvement":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100621847","clinical-biochemical-and-epigenetic-profile-of-pediatric-behet-disease-100621847",false,"NCT07375940","Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease","Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease: Similarities and Differences From Adult Patients and Looking for Potential Biomarkers.","PED-BD","Cases Inclusion Criteria :\n\n* BD diagnosis according to at least one of the three sets of classification criteria \\[International Criteria for Behçet's Disease (ICBD), International Study Group (ISG) and Pediatric Behçet's disease criteria PEDBD)\\];\n* Age 6 months to 70 years old.\n* Written informed consent from appropriate legal representative(s), and assent from patients who have not reached the age of consent.\n\nCases Exclusion Criteria:\n\n* Patients who do not meet the BD criteria OR\n* Patients for whom an alternative diagnosis was not investigated and\u002For excluded OR\n* Absence of a written informed consent.\n\nHealthy pediatric controls:\n\n* Patients evaluated at the Meyer Children's Hospital IRCCS Rheumatology Outpatient Clinic who are scheduled to undergo routine hematochemical tests, not for suspected inflammatory or autoimmune conditions.\n* Age \\\u003C 18 years, matched 1:1 by age and sex with the pediatric Behçet disease (BD) cohort.\n* Absence of recent or ongoing inflammatory conditions, verified through structured medical history and physical examination.\n* No clinical signs suggestive of chronic autoinflammatory or autoimmune diseases at physical examination .\n* No recent prolonged use (more than 7 consecutive days within the past 4 weeks) of anti-inflammatory, glucocorticoids, immunomodulatory, therapies or antibiotics.\n* Written informed consent from the legal guardian(s) and assent from minors when appropriate.\n\nHealthy Controls Exclusion Criteria\n\n* Diagnosis of acute or chronic inflammatory, autoimmune, or autoinflammatory conditions after the collection of structured medical history and physical examination\n* Current or recent prolonged use (more than 7 consecutive days within the past 4 weeks) of anti-inflammatory drugs, gluccocorticoids, immunomodulatory agents, or antibiotics.\n* Routine blood tests not performed during the visit.\n* Absence of written informed consent.","ALL","6 Months","70 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","Behçet disease (BD) is a chronic multisystem inflammatory disorder with a relapsing-remitting course. Pediatric-onset BD is rare and characterized by marked clinical heterogeneity, frequent incomplete presentation at disease onset, and limited availability of pediatric-specific outcome measures and biomarkers.\n\nThis prospective multicenter study aims to comprehensively characterize the clinical, biochemical, genetic, and epigenetic profiles of pediatric patients with Behçet disease and to compare them with adult BD patients and healthy pediatric controls.\n\nThe study focuses on the identification of disease-associated cytokine patterns, circulating microRNA profiles, DNA methylation signatures, and genetic variants associated with monogenic autoinflammatory diseases presenting with a Behçet-like phenotype.\n\nBy integrating clinical data with multi-omic analyses, this study seeks to identify biologically and clinically meaningful patient subgroups, improve disease stratification, and explore potential biomarkers of disease activity and remission in pediatric Behçet disease.",[28],"Behcet Disease and Vascular Involvement","RECRUITING","2026-01-22",{"date":32,"type":33},"2026-01-29","ACTUAL",{"date":35,"type":33},"2026-01-12",{"date":37,"type":22},"2036-01",{"name":39,"class":40},"Meyer Children's Hospital IRCCS","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100587231","phase-3-immunosuppressive-therapy-alone-versus-plus-oral-anticoagulation-in-the-treatment-of-vt-associated-with-behcets-disease-100587231","NCT06925698","Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","Immunosuppressive Therapy Alone Versus Immunosuppressive Therapy Plus Oral Anticoagulation in the Treatment of Lower Extremity Venous Thrombosis Associated With Behcet's Disease","BETTER","Inclusion Criteria:\n\n* Participants must meet the following criteria to be eligible for the study:\n\nAge between 18-50 years old. Diagnosed with Behçet's Disease according to the International Study Group (ISG) criteria.\n\nNo prior vascular involvement or no previous immunosuppressive therapy for vascular involvement.\n\nConfirmed venous thrombosis in the lower extremity within the last 14 days before randomization.\n\nVenous thrombosis diagnosis confirmed by:\n\nNon-compressible venous segment in ultrasound, OR A significant (\\>4 mm) increase in thrombus diameter in an already abnormal segment, OR New intraluminal filling defect on venography, CT, or MR angiography.\n\nFemale participants must:\n\nNot be pregnant or breastfeeding. Use effective contraception if of childbearing potential. Be postmenopausal (no menses for at least 1 year) or have undergone surgical sterilization.\n\nAbility to provide written informed consent and comply with study requirements.\n\nExclusion Criteria:\n\n* Participants will be excluded if they meet any of the following criteria:\n\nPresence of any aneurysm. Chronic multisystemic disease other than Behçet's Disease. History of intolerance to Rivaroxaban. Use of immunosuppressive drugs (azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, TNF inhibitors, or interferon-gamma) within the last 6 months.\n\nProlonged corticosteroid use (\\>3 months) for Behçet's Disease mucocutaneous symptoms.\n\nPrior anticoagulant therapy:\n\nLow molecular weight heparin, fondaparinux, or unfractionated heparin for \\>48 hours before randomization.\n\nMore than one dose of vitamin K antagonists before randomization. Thrombectomy, vena cava filter placement, or fibrinolytic therapy for the current thrombotic episode.\n\nPlanned administration of a live vaccine within 30 days after randomization. Clinically significant acute or uncontrolled chronic diseases (e.g., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, or infectious diseases) that may interfere with study results.\n\nPlanned surgical procedure or significant medical condition deemed unsuitable for the study by the investigator.\n\nHistory of malignancy within the last 5 years (except adequately treated basal or squamous cell carcinoma or carcinoma in situ of the cervix).\n\nRenal impairment (Creatinine clearance \\\u003C30 ml\u002Fmin). Severe liver disease (e.g., acute hepatitis, active chronic hepatitis, cirrhosis, or ALT \\>3 times the upper limit).\n\nActive bleeding or high bleeding risk contraindicating anticoagulant therapy. Uncontrolled hypertension (SBP \\>180 mmHg or DBP \\>110 mmHg). Severe anemia (Hemoglobin \\\u003C10 mg\u002FdL). Women who are pregnant, breastfeeding, or of childbearing potential without contraception.\n\nUse of strong CYP3A4 inhibitors or inducers (e.g., protease inhibitors, systemic ketoconazole, rifampin, carbamazepine, phenytoin).\n\nParticipation in another experimental drug study within the last 30 days. Life expectancy of less than 3 months. History of serious infections within the last 60 days (e.g., bacterial endocarditis, tuberculosis, opportunistic infections).\n\nActive substance or alcohol abuse or history of substance dependence within the last year.\n\nPositive screening for Hepatitis B surface antigen, Hepatitis C antibody, or known HIV-1 infection.\n\nKnown coagulation disorders or laboratory abnormalities (e.g., DMID toxicity scale Grade 3 or higher).\n\nHistory of suicidal behavior in the last 6 months or suicidal ideation (C-SSRS type 4 or 5) in the last 2 months.","18 Years","50 Years",{"count":52,"type":22},110,[54],"PHASE3","This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).",[57,28,58,59],"Behcet Disease","Deep Venous Thromboses","Post Thrombotic Syndrome",[61,62,63,64],"Behcet's disease","Deep venous thrombosis","Anticoagulant therapy","Rivaroxaban","NOT_YET_RECRUITING","2025-04-07",{"date":68,"type":33},"2025-04-13",{"date":70,"type":22},"2025-04-30",{"date":72,"type":22},"2028-04-01",{"name":74,"class":40},"Marmara University"]